Old drugs, new uses: Drug repurposing in hematological malignancies

Vijay P. Kale, Hasan Habib, Robert Chitren, Milan Patel, Kartick C. Pramanik, Subash C. Jonnalagadda, Kishore Challagundla, Manoj K. Pandey

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Discovery and development of novel anti-cancer drugs are expensive and time consuming. Systems biology approaches have revealed that a drug being developed for a non-cancer indication can hit other targets as well, which play critical roles in cancer progression. Since drugs for non-cancer indications would have already gone through the preclinical and partial or full clinical development, repurposing such drugs for hematological malignancies would cost much less, and drastically reduce the development time, which is evident in case of thalidomide. Here, we have reviewed some of the drugs for their potential to repurpose for treating the hematological malignancies. We have also enlisted resources that can be helpful in drug repurposing.

Original languageEnglish (US)
JournalSeminars in Cancer Biology
DOIs
StateAccepted/In press - 2020

Keywords

  • Drug development
  • Drug repositioning
  • Drug repurposing
  • Hematological malignancies
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Old drugs, new uses: Drug repurposing in hematological malignancies'. Together they form a unique fingerprint.

Cite this